Expansion of CD11b+Ly6G+Ly6Cint cells driven by medroxyprogesterone acetate in mice bearing breast tumors restrains NK cell effector functions

Cancer Immunology, Immunotherapy

Volumn 62, Issue 12, 2013, Pages 1781-1795

  Spallanzani, Raúl Germán ^a   Dalotto Moreno, Tomás ^a   Raffo Iraolagoitia, Ximena Lucía ^a   Ziblat, Andrea ^a   Domaica, Carolina Inés ^a   Avila, Damián Ezequiel ^a,b   Rossi, Lucas Ezequiel ^a   Fuertes, Mercedes Beatriz ^a,c   Battistone, María Agustina ^a   Rabinovich, Gabriel Adrián ^a,c   Salatino, Mariana ^a   Zwirner, Norberto Walter ^a,c  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b FACULTAD DE CIENCIAS EXACTAS   (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Breast cancer; Medroxyprogesterone acetate; Myeloid derived suppressor cells; NK cells

Indexed keywords

CD11B ANTIGEN; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; MEDROSTERONA; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW; BONE MARROW CELL; BREAST TUMOR; CELL DIFFERENTIATION; CELL EXPANSION; CELL FUNCTION; CELL LINE; CELL MOTILITY; CONTROLLED STUDY; CYTOTOXICITY; DEGRANULATION; DRUG EFFICACY; DRUG EXPOSURE; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOSURVEILLANCE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD11B; ANTIGENS, LY; ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; KILLER CELLS, NATURAL; MEDROXYPROGESTERONE ACETATE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYELOID CELLS; RECEPTORS, GLUCOCORTICOID; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED;

EID: 84890335373     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1483-x     Document Type: Article

References (55)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917. doi: 10.1002/ijc.25516
2. Santen RJ, Manni A, Harvey H, Redmond C (1990) Endocrine treatment of breast cancer in women. Endocr Rev 11:221-265. doi: 10.1210/edrv-11-2-221
3. Liedtke C, Mazouni C, Hess KR et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275-1281. doi: 10.1200/JCO.2007.14.4147
4. Tan DS, Marchio C, Jones RL, Savage K, Smith IE, Dowsett M, Reis-Filho JS (2008) Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 111:27-44. doi: 10.1007/s10549-007-9756-8
5. Chlebowski RT, Anderson GL (2012) Changing concepts: menopausal hormone therapy and breast cancer. J Natl Cancer Inst 104:517-527. doi: 10.1093/jnci/djs014
6. Nelson HD, Walker M, Zakher B, Mitchell J (2012) Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the US Preventive Services Task Force recommendations. Ann Intern Med 157:104-113. doi: 10.7326/0003-4819-157-2-201207170-00466
7. Aupperlee M, Kariagina A, Osuch J, Haslam SZ (2005) Progestins and breast cancer. Breast Dis 24:37-57
8. Lange CA, Sartorius CA, Abdel-Hafiz H, Spillman MA, Horwitz KB, Jacobsen BM (2008) Progesterone receptor action: translating studies in breast cancer models to clinical insights. Adv Exp Med Biol 630:94-111. doi: 10.1007/978-0-387-78818-0-7
9. Lange CA (2008) Challenges to defining a role for progesterone in breast cancer. Steroids 73:914-921. doi: 10.1016/j.steroids.2007.12.023
10. Giulianelli S, Vaque JP, Soldati R et al (2012) Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters. Cancer Res 72:2416-2427. doi: 10.1158/0008-5472.CAN-11-3290
11. Cerliani JP, Guillardoy T, Giulianelli S et al (2011) Interaction between FGFR-2, STAT5, and progesterone receptors in breast cancer. Cancer Res 71:3720-3731. doi: 10.1158/0008-5472.CAN-10-3074
12. Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S (2006) Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 176:284-290
13. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, Bronte V (2010) Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 22:238-244. doi: 10.1016/j.coi.2010.01.021
14. Kusmartsev S, Gabrilovich DI (2006) Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 55:237-245. doi: 10.1007/s00262-005-0048-z
15. Sinha P, Parker KH, Horn L, Ostrand-Rosenberg S (2012) Tumor-induced myeloid-derived suppressor cell function is independent of IFN-gamma and IL-4Ralpha. Eur J Immunol 42:2052-2059. doi: 10.1002/eji.201142230
16. Lanier LL (2008) Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9:495-502. doi: 10.1038/ni1581
17. Moretta L, Bottino C, Pende D, Castriconi R, Mingari MC, Moretta A (2006) Surface NK receptors and their ligands on tumor cells. Semin Immunol 18:151-158. doi: 10.1016/j.smim.2006.03.002
18. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9:503-510. doi: 10.1038/ni1582
19. Zwirner NW, Domaica CI (2010) Cytokine regulation of natural killer cell effector functions. Biofactors 36:274-288. doi: 10.1002/biof.107
20. Zwirner NW, Fuertes MB, Girart MV, Domaica CI, Rossi LE (2007) Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system. Cytokine Growth Factor Rev 18:159-170. doi: 10.1016/j.cytogfr.2007.01.013
21. Mamessier E, Sylvain A, Bertucci F et al (2011) Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Cancer Res 71:6621-6632. doi: 10.1158/0008-5472.CAN-11-0792
22. Li H, Han Y, Guo Q, Zhang M, Cao X (2009) Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta1. J Immunol 182:240-249
23. Hoechst B, Voigtlaender T, Ormandy L et al (2009) Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 50:799-807. doi: 10.1002/hep.23054
24. Elkabets M, Ribeiro VS, Dinarello CA, Ostrand-Rosenberg S, Di Santo JP, Apte RN, Vosshenrich CA (2010) IL-1beta regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol 40:3347-3357. doi: 10.1002/eji.201041037
25. Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC et al (2011) Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice. Cancer Res 71:5101-5110. doi: 10.1158/0008-5472.CAN-10-2670
26. Liu C, Yu S, Kappes J, Wang J, Grizzle WE, Zinn KR, Zhang HG (2007) Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 109:4336-4342. doi: 10.1182/blood-2006-09-046201
27. Nausch N, Galani IE, Schlecker E, Cerwenka A (2008) Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells. Blood 112:4080-4089. doi: 10.1182/blood-2008-03-143776
28. Simpson KD, Templeton DJ, Cross JV (2012) Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment. J Immunol 189:5533-5540. doi: 10.4049/jimmunol.1201161
29. duPre SA, Redelman D, Hunter KW Jr (2008) Microenvironment of the murine mammary carcinoma 4T1: endogenous IFN-gamma affects tumor phenotype, growth, and metastasis. Exp Mol Pathol 85:174-188. doi: 10.1016/j.yexmp.2008.05.002
30. Yan HH, Pickup M, Pang Y et al (2010) Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res 70:6139-6149. doi: 10.1158/0008-5472.CAN-10-0706
31. Olkhanud PB, Baatar D, Bodogai M et al (2009) Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res 69:5996-6004. doi: 10.1158/0008-5472.CAN-08-4619
32. Tkach M, Coria L, Rosemblit C et al (2012) Targeting Stat3 induces senescence in tumor cells and elicits prophylactic and therapeutic immune responses against breast cancer growth mediated by NK cells and CD4+ T cells. J Immunol 189:1162-1172. doi: 10.4049/jimmunol.1102538
33. Alvarez LD, Marti MA, Veleiro AS, Misico RI, Estrin DA, Pecci A, Burton G (2008) Hemisuccinate of 21-hydroxy-6,19-epoxyprogesterone: a tissue-specific modulator of the glucocorticoid receptor. ChemMedChem 3:1869-1877. doi: 10.1002/cmdc.200800256
34. Molinero LL, Fuertes MB, Fainboim L, Rabinovich GA, Zwirner NW (2003) Up-regulated expression of MICA on activated T lymphocytes involves Lck and Fyn kinases and signaling through MEK1/ERK, p38 MAP kinase, and calcineurin. J Leukoc Biol 73:815-822. doi: 10.1189/jlb.0602329
35. Saudemont A, Burke S, Colucci F (2010) A simple method to measure NK cell cytotoxicity in vivo. Methods Mol Biol 612:325-334. doi: 10.1007/978-1-60761- 362-6-22
36. Marigo I, Bosio E, Solito S et al (2010) Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 32:790-802. doi: 10.1016/j.immuni.2010.05.010
37. Courtin A, Communal L, Vilasco M et al (2012) Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. Breast Cancer Res Treat 131:49-63. doi: 10.1007/s10549-011-1394-5
38. Bamberger CM, Else T, Bamberger AM, Beil FU, Schulte HM (1999) Dissociative glucocorticoid activity of medroxyprogesterone acetate in normal human lymphocytes. J Clin Endocrinol Metab 84:4055-4061. doi: 10.1210/jc.84.11.4055
39. Dressel R, Nolte J, Elsner L, Novota P, Guan K, Streckfuss-Bomeke K, Hasenfuss G, Jaenisch R, Engel W (2010) Pluripotent stem cells are highly susceptible targets for syngeneic, allogeneic, and xenogeneic natural killer cells. FASEB J 24:2164-2177. doi: 10.1096/fj.09-134957
40. Rabinovich GA, Sotomayor E, Gabrilovich D (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267-296. doi: 10.1146/annurev.immunol.25.022106.141609
41. Tkach M, Rosemblit C, Rivas MA et al (2013) p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth. Endocr Relat Cancer 20:197-212. doi: 10.1530/ERC-12-0194
42. Diaz Flaque MC, Vicario R, Proietti CJ, Izzo F, Schillaci R, Elizalde PV (2013) Progestin drives breast cancer growth by inducing p21(CIP1) expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2. Steroids 78:559-567. doi: 10.1016/j.steroids.2012.11.003
43. Ling X, Arlinghaus RB (2005) Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 65:2532-2536. doi: 10.1158/0008-5472.CAN-04-2425
44. Younos IH, Dafferner AJ, Gulen D, Britton HC, Talmadge JE (2012) Tumor regulation of myeloid-derived suppressor cell proliferation and trafficking. Int Immunopharmacol 13:245-256. doi: 10.1016/j.intimp.2012.05.002
45. Salatino M, Dalotto T, Croci DO, Mendez Huergo S, Dergan Dylon S, Cerliani J, Toscano M, Rabinovich G et al (2013) Progesterone-induced immunosuppression thwarts immunosurveillance to tumors and promotes lung metastasis in a breast cancer model [abstract]. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 6-10 April 2013, Washington, DC, Philadelphia (PA) AACR; 2013. Abstract nr 449
46. Benson JR, Teo KA (2012) Breast cancer local therapy: what is its effect on mortality? World J Surg 36:1460-1474. doi: 10.1007/s00268-012-1468-5
47. Darby S, McGale P, Correa C et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378:1707-1716. doi: 10.1016/S0140-6736(11)61629-2
48. Nagaraj S, Gabrilovich DI (2012) Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells. Semin Cancer Biol 22:282-288. doi: 10.1016/j.semcancer.2012.01.010
49. Fortin C, Huang X, Yang Y (2012) NK cell response to vaccinia virus is regulated by myeloid-derived suppressor cells. J Immunol 189:1843-1849. doi: 10.4049/jimmunol.1200584
50. Sceneay J, Chow MT, Chen A et al (2012) Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res 72:3906-3911. doi: 10.1158/0008-5472.CAN-11-3873
51. Zhu J, Huang X, Yang Y (2012) Myeloid-derived suppressor cells regulate natural killer cell response to adenovirus-mediated gene transfer. J Virol 86:13689-13696. doi: 10.1128/JVI.01595-12
52. Yu J, Du W, Yan F et al (2013) Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 190:3783-3797. doi: 10.4049/jimmunol.1201449
53. Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB (2002) Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 196:459-468. doi: 10.1084/jem.20020121
54. Sato N, Saga Y, Mizukami H et al (2012) Downregulation of indoleamine-2,3-dioxygenase in cervical cancer cells suppresses tumor growth by promoting natural killer cell accumulation. Oncol Rep 28:1574-1578. doi: 10.3892/or 2012.1984
55. Wang D, Saga Y, Mizukami H et al (2012) Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy. Int J Oncol 40:929-934. doi: 10.3892/ijo 2011.1295